Juan's Interview & Publication
SYNLAB Spain
Juan Carlos Triviño
Head of Bioinformatics Department at Sistemas Genomicos
What inspired your research, and what did it cover?
The study combined the latest technologies in genetics and transcriptomics to provide an overview of tumour physiology. It was carried out by Dr José Mordoh's team, and I am very glad to have had the opportunity to participate in it.
Looking at the potential of your findings, what difference can they make?
The potential is high; the possibility of using RNA technologies to define specific vaccines opens up an exciting field for research. This case could be considered a proof of concept for applying these results to new cases and new types of tumours.
Publication
An Update of Cutaneous Melanoma Patients Treated in Adjutancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases
National Library of Medicine – https://pubmed.ncbi.nlm.nih.gov/35432383/
In phase I it was observed that the toxicity of the vaccines was minimal and that patients had long intervals without relapse. In phase II, it was demonstrated that vaccinated patients had a longer distant metastasis-free survival (DMFS) than those treated with IFNα2b, and that cellular immunity was triggered.